Novo Nordisk (NVO) said Monday it is planning to invest 432 million euros ($507.1 million) to upgrade its tabletting facility in Athlone, Ireland.
This tabletting site will offer additional production capacity for current and future GLP-1 treatments, according to the Danish drug manufacturer.
Novo Nordisk said it has already started construction work on the facility, with completion anticipated from the end of next year through 2028.
Shares of the company were down 1.1% in recent Monday premarket activity.